Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ascentage Pharma Group International
Headquarters: Suzhou, China
Website: http://www.ascentagepharma.com...
Year Founded: 2009
Status: Public
Industry Sector: HealthTechnology
CEO: Da Jan Yang, MD, PhD
Number Of Employees: 583
Enterprise Value: $1,087,089,627
PE Ratio: -27.63
Exchange/Ticker 1: HKEX:6855
Exchange/Ticker 2: NASDAQ:AAPG
Latest Market Cap: $1,662,828,382
BioCentury | Jan 24, 2025
Finance
Ascentage lists on NASDAQ as Odyssey, Sionna, Aardvark plot IPOs
In BioCentury’s Finance Report, two more companies plan Hong Kong listings; Disc Medicine, Arctic raise cash
BioCentury | Jun 18, 2024
Deals
Deals Report: Syncona merging Freeline, SwanBio to form Spur
Plus: AbbVie licenses TL1A mAb from FutureGen for IBD, and updates from Takeda, Ascentage, Pfizer, ProFound and more
BioCentury | Jun 14, 2024
Finance
Public Equity Report: IPO action from QuantumPharm, Ascentage, Alumis, Telix
Plus: Fundraising by Avidity, Ultragenyx, ProKidney, Disc Medicine, Opthea and Replimmune
BioCentury | Feb 4, 2023
Market Access
Rare diseases, MNCs grow presence on China’s NRDL
Even with big price reductions, China’s national reimbursement list is a lure for drug developers around the globe
BioCentury | Dec 14, 2022
Deals
Dec. 13 Quick Takes: GSK grows oligo presence with Wave collaboration
Plus: Flagship launches Montai and updates from Peroxitech, Tellus, Ascentage, Aeon, Genomics England, Metriopharm
BioCentury | Nov 30, 2021
Management Tracks
Tolstrup stepping up at Lundbeck
Plus: Neomorph, Becton Dickinson, Karuna, Ascentage and Hummingbird
BioCentury | Jul 14, 2021
Deals
Innovent, Ascentage pave new model for China biotech deals
Innovent to take $50M equity stake in Ascentage and provide $30M up front, up to $115M in milestones
BioCentury | Mar 1, 2021
Deals
With Phase III started in head and neck cancer, Debiopharm partners lead program with Germany’s Merck
Debiopharm will bank €188 million ($226.6 million) for pipeline development now that the biotech has partnered lead program xevinapant with Merck KGaA, adding the German biopharma’s
BioCentury | Sep 4, 2020
Product Development
Rain to advance growing precision oncology pipeline with $63M series B
A crossover-heavy $63 million series B round will provide Rain with enough money to bring what it says is its new lead program — a newly licensed cancer therapy from Daiichi Sankyo —
Items per page:
1 - 10 of 27